Riskpilot← Back to searchSign inGet full accessDANIPHARM A/S
A/SActiveCVR 12335040Englandsvej 350-356Manufacture of basic pharmaceutical products · NACE 2110Est. 198824 employees
Revenue 2025
DKK 37,6M
+10% vs 2024
EBITDA margin
50.9%
+109% vs 2024
Equity ratio
53.3%
Financial strength
Net profit 2025
DKK 13,7M
+168% vs 2024
| Revenue | DKK 37,6M | +10% |
| EBITDA | DKK 19,1M | +109% |
| Net profit | DKK 13,7M | +168% |
| Total assets | DKK 113M | +18% |
| Equity | DKK 60,3M | +29% |
| Employees | 24 | — |
Legal name
DANIPHARM A/S
CVR number
12335040
Legal form
Aktieselskab
NACE code
2110 · Manufacture of basic pharmaceutical products
Founded
1. august 1988
Share capital
DKK 500.000
Employees
24 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør eller af et bestyrelsesmedlem.
Company purpose
Selskabets formål er at drive handel, produktion og forskning
Address
Englandsvej 350-356
Phone
+4570103020
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.401 | 84.814 | 90.098 | 85.065 | 85.172 | 93.581 | 35.699 | 42.946 | 91.597 | 29.395 | 34.935 | 35.152 | 34.065 | 37.587 |
| Staff expenses | -13.514 | -18.601 | -18.272 | -19.538 | -20.166 | -21.183 | -21.231 | -20.517 | -22.051 | -22.491 | -23.416 | -24.795 | -24.886 | -18.442 |
| EBITDA | 3.595 | 3.302 | 12.670 | 15.322 | 20.685 | 15.844 | 14.468 | 22.429 | 9.588 | 6.903 | 11.519 | 10.356 | 9.179 | 19.145 |
| Depreciation & amort. | -3.635 | -2.627 | -814 | -886 | -1.363 | -1.730 | -1.470 | -1.726 | -2.186 | -2.334 | -2.302 | -2.300 | -2.152 | -2.083 |
| EBIT | -40 | 674 | 11.856 | 14.436 | 19.322 | 14.114 | 12.999 | 20.703 | 7.402 | 4.569 | 9.217 | 8.056 | 7.028 | 17.062 |
| Net financials | -634 | -311 | -224 | 160 | 216 | 396 | 119 | 225 | -9 | -797 | 1.282 | -1.151 | -476 | 521 |
| Profit before tax | -335 | 364 | 11.632 | 14.597 | 19.538 | 14.511 | 13.117 | 20.928 | 7.393 | 3.772 | 10.499 | 6.906 | 6.552 | 17.583 |
| Tax | 169 | 131 | 2.760 | 3.331 | 4.298 | 3.191 | 2.886 | 4.603 | 1.626 | 828 | 2.308 | 1.515 | 1.438 | 3.866 |
| Net profit | -504 | 232 | 8.872 | 11.266 | 15.240 | 11.319 | 10.231 | 16.325 | 5.767 | 2.944 | 8.191 | 5.391 | 5.114 | 13.717 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 56.531 | 28.537 | 30.046 | 42.828 | 56.015 | 64.827 | 36.363 | 33.983 | 68.942 | 73.178 | 78.307 | 87.076 | 95.569 | 112.993 |
| Equity | 5.840 | 6.436 | 15.296 | 26.516 | 41.756 | 50.601 | 24.833 | 21.157 | 26.924 | 29.869 | 36.059 | 41.450 | 46.564 | 60.281 |
| Long-term debt | 726 | 100 | 0 | 0 | 0 | 567 | 0 | 0 | 4.600 | 3.200 | 0 | 0 | 1.659 | 3.956 |
| Short-term debt | 47.866 | 19.614 | 12.450 | 13.910 | 12.670 | 12.807 | 10.604 | 11.536 | 35.723 | 38.301 | 40.447 | 43.781 | 45.722 | 47.221 |
| Total debt | 48.592 | 19.715 | 12.450 | 13.910 | 12.670 | 13.373 | 10.604 | 11.536 | 40.323 | 41.501 | 40.447 | 43.781 | 47.381 | 51.177 |
EBITDA margin
50.9%
This company
15.8%
Market median
+222% vs market
20122025
Equity ratio
53.3%
This company
38.2%
Market median
+40% vs market
20122025
Return on equity
22.8%
This company
18.4%
Market median
+24% vs market
20122025
Net profit margin
36.5%
This company
8.1%
Market median
+351% vs market
20122025
Asset turnover
0.33×
This company
1.12×
Market median
-71% vs market
20122025
Debt / equity
0.87×
This company
0.62×
Market median
+40% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via CVR / Virk · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via CVR / Virk · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via CVR / Virk · Period 2011-07-01 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ET | Audit | 1988 | — | — |
EV Management | Management | 1996 | — | — |
NO Management | Management | 1988 | — | — |
PR Management | Management | 2006 | — | — |
PE Management | Management | 1988 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2004 | — | — | |
| Board of Directors | 2005 | — | — | |
| Chairman | 2006 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
H&P Rørvig Holding A/S | Company | 100.0% | 100.0% | 2009 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
H&P Rørvig Holding A/S
DANIPHARM A/S Board members of DANIPHARM A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Tronborg Andersen | Audit | 0 companies |
| Erik Vilhelm Balslev | Management | 0 companies |
| Niels Otto Thiesen | Management | 0 companies |
| Peter Rørvig | Management | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |
| Svend Blankholm | Board of Directors | 0 companies |
| Helle Rørvig | Board of Directors | 0 companies |
| Niels Ulrik Heine | Chairman | 0 companies |